A novel mutation leading to the lethal form of carnitine palmitoyltransferase type-2 deficiency

J Pediatr Endocrinol Metab. 2019 Jul 26;32(7):781-783. doi: 10.1515/jpem-2019-0038.

Abstract

Background The clinical phenotypes of carnitine palmitoyltransferase type-2 deficiency (CPT2D) are classified into lethal neonatal, severe infantile and muscle forms. The rarest form is the lethal neonatal form. Case presentation The patient was hypotonic and bradycardic at admission. Blood urea nitrogen and creatinine were high. He had polycystic kidneys, patent foramen ovale and aortic valve insufficiency. Cranial magnetic resonance imaging (MRI) revealed increased signal intensities in the periventricular white matter. Tandem mass spectrometry (MS) analysis was compatible with CPT2D. We found a homozygous in-frame deletion in the CPT2 gene using next-generation sequencing. Conclusions We identified a novel mutation leading to the lethal form of CPT2D with polycystic kidney, cardiac malformation and cranial MRI findings. Our findings expand the spectrum of causative mutations and clinical findings in CPT2D.

Keywords: carnitine palmitoyltransferase 2 deficiency; cranial MRI; mutation.

Publication types

  • Case Reports

MeSH terms

  • Carnitine O-Palmitoyltransferase / deficiency*
  • Carnitine O-Palmitoyltransferase / genetics*
  • Child, Preschool
  • Fatal Outcome
  • Gene Deletion*
  • Homozygote
  • Humans
  • Male
  • Metabolism, Inborn Errors / genetics
  • Metabolism, Inborn Errors / pathology*
  • Mutation*
  • Phenotype

Substances

  • Carnitine O-Palmitoyltransferase

Supplementary concepts

  • Carnitine palmitoyl transferase 2 deficiency